Sera Prognostics' PreTRM Test Cuts NICU Admissions by 22% in First-Time Pregnancies
Event summary
- Sera Prognostics' PreTRM Test-guided care reduced NICU admissions by 22% in first-time pregnancies, per PRIME trial subgroup analysis (n=1,783).
- Study published July 9, 2026 in The Journal of Maternal-Fetal & Neonatal Medicine.
- Screening efficiency: 28 tests needed to prevent one NICU admission; 30% reduction in severe composite morbidity.
- Interventions included progesterone, low-dose aspirin, and care management.
The big picture
Sera Prognostics' results address a critical gap in preterm birth prediction for first-time mothers, who represent 40% of U.S. births but lack prior obstetric history for risk assessment. The findings come as the U.S. maintains a D+ grade for preterm birth rates per March of Dimes, highlighting unmet need. This positions Sera's biomarker approach as a potential new standard in high-risk pregnancy management.
What we're watching
- Market Adoption
- Whether payers and providers will broadly adopt PreTRM-guided care for first-time pregnancies, given its demonstrated cost savings potential.
- Regulatory Pathway
- The pace at which Sera Prognostics secures expanded reimbursement coverage for the PreTRM Test, critical for scaling its impact.
- Competitive Positioning
- How this data differentiates Sera from traditional risk assessment tools in the $25B preterm birth management market.